Alector, Inc. (NASDAQ:ALEC) Receives $4.00 Average Target Price from Brokerages

Alector, Inc. (NASDAQ:ALEC) has earned a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $4.00.

Several equities analysts have commented on ALEC shares. Morgan Stanley reaffirmed an “underweight” rating and issued a $1.50 price objective (down previously from $3.00) on shares of Alector in a research report on Friday, March 7th. HC Wainwright upped their price objective on Alector from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 9th.

Hedge Funds Weigh In On Alector

Several hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new stake in shares of Alector in the 1st quarter worth $126,000. Acadian Asset Management LLC lifted its holdings in shares of Alector by 39.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company’s stock worth $1,768,000 after buying an additional 410,205 shares during the period. Jane Street Group LLC lifted its holdings in shares of Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after buying an additional 11,618 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Alector by 25.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after buying an additional 274,341 shares during the period. Finally, Almitas Capital LLC lifted its holdings in shares of Alector by 12.9% in the 1st quarter. Almitas Capital LLC now owns 321,568 shares of the company’s stock worth $396,000 after buying an additional 36,723 shares during the period. Institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

NASDAQ ALEC opened at $1.46 on Friday. The company has a market cap of $145.99 million, a P/E ratio of -1.16 and a beta of 0.71. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.34 and a current ratio of 3.34. The business’s 50 day moving average price is $1.24 and its 200-day moving average price is $1.52. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $6.78.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.